title: Overexpression of the polarity protein PAR-3 in clear cell renal cell carcinoma is associated with poor prognosis.
abstract: The partition-defective 3 (PAR-3) protein is implicated in the development and maintenance of cell polarity and is associated with proteins that mediate the changes in cytoskeleton organization required for cell polarity establishment. In this work, we used two original primary cell lines (R-180 and R-305) derived from clear cell Renal Cell Carcinoma (ccRCC) surgical specimens of a patient with unfavorable clinical course (R-180 cells) and a patient with favorable prognosis (R-305 cells) to identify genetic and molecular features that may explain the survival difference of the two patients. The cytogenetic analysis of these cell lines revealed that the PARD3 gene was amplified only in the R-180 cell line that was derived from an aggressive ccRCC. PARD3 gene amplification was associated with overexpression of the encoded protein and altered cytoskeleton organization. Consistently, PARD3 knockdown in R-180 cells restored the cytoskeleton organization and reduced cell migration in comparison to non-transfected cells. Immunohistochemical analysis of ccRCC samples from a cohort of 96 patients with a follow-up of 6 years revealed that PAR-3 overexpression was correlated with poor survival. Our results suggest that PAR-3 has a role in the clinical aggressiveness of ccRCC, possibly by promoting cell migration.
authors.forename: F
authors.initials: F
authors.lastname: Dugay
authors.forename: X
authors.initials: X
authors.lastname: Le Goff
authors.forename: N
authors.initials: N
authors.lastname: Rioux-Leclerq
authors.forename: F
authors.initials: F
authors.lastname: Chesnel
authors.forename: F
authors.initials: F
authors.lastname: Jouan
authors.forename: C
authors.initials: C
authors.lastname: Henry
authors.forename: F
authors.initials: F
authors.lastname: Cabillic
authors.forename: G
authors.initials: G
authors.lastname: Verhoest
authors.forename: C
authors.initials: C
authors.lastname: Vigneau
authors.forename: Y
authors.initials: Y
authors.lastname: Arlot-Bonnemains
authors.forename: M A
authors.initials: MA
authors.lastname: Belaud-Rotureau
mesh_terms: D048868:Adaptor Proteins, Signal Transducing; D000328:Adult; D000368:Aged; D015153:Blotting, Western; D002292:Carcinoma, Renal Cell / Q000378:metabolism* / Q000401:mortality / Q000473:pathology*; D018797:Cell Cycle Proteins / Q000096:biosynthesis*; D045744:Cell Line, Tumor; D002465:Cell Movement; D003599:Cytoskeleton / Q000378:metabolism / Q000473:pathology; D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D007680:Kidney Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology*; D008297:Male; D008565:Membrane Proteins / Q000096:biosynthesis*; D008875:Middle Aged; D011379:Prognosis
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D018797:Cell Cycle Proteins; D008565:Membrane Proteins; C509689:PARD3 protein, human